These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 37486514)

  • 1. Modern Approaches to Mouse Genome Editing Using the CRISPR-Cas Toolbox and Their Applications in Functional Genomics and Translational Research.
    Monteiro CJ; Heery DM; Whitchurch JB
    Adv Exp Med Biol; 2023; 1429():13-40. PubMed ID: 37486514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.
    Li ZH; Wang J; Xu JP; Wang J; Yang X
    Mil Med Res; 2023 Mar; 10(1):12. PubMed ID: 36895064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Developments in CRISPR/Cas-based Functional Genomics and their Implications for Research Using Zebrafish.
    Prykhozhij SV; Caceres L; Berman JN
    Curr Gene Ther; 2017; 17(4):286-300. PubMed ID: 29173171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Genetically Engineered Mouse Models (GEMMs) Using CRISPR Mediated Genome Editing.
    Desjardins J; Cowan M; Yamanaka Y
    Methods Mol Biol; 2022; 2429():515-531. PubMed ID: 35507186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.
    Zhang D; Li Z; Li JF
    J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosting targeted genome editing using the hei-tag.
    Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
    Elife; 2022 Mar; 11():. PubMed ID: 35333175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime editing in plants and mammalian cells: Mechanism, achievements, limitations, and future prospects.
    Hillary VE; Ceasar SA
    Bioessays; 2022 Sep; 44(9):e2200032. PubMed ID: 35750651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9.
    Zhang Y; Karakikes I
    Trends Cardiovasc Med; 2021 Aug; 31(6):341-348. PubMed ID: 32603681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in the genetic editing technologies: CRISPR-Cas and beyond.
    Mingarro G; Del Olmo ML
    Gene; 2023 Feb; 852():147064. PubMed ID: 36435506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progresses in CRISPR genome editing in plants].
    Li H; Xie K
    Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1700-1711. PubMed ID: 29082718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of CRISPR-Cas9 prime editing for cardiovascular disease research and therapy.
    Bharucha N; Arias A; Karakikes I
    Curr Opin Cardiol; 2022 Sep; 37(5):413-418. PubMed ID: 35880456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
    Dong W; Kantor B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals.
    Seruggia D; Montoliu L
    Transgenic Res; 2014 Oct; 23(5):707-16. PubMed ID: 25092533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas genome editing in plants: mechanisms, applications, and overcoming bottlenecks.
    Hwarari D; Radani Y; Ke Y; Chen J; Yang L
    Funct Integr Genomics; 2024 Mar; 24(2):50. PubMed ID: 38441816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Bioinformatics Tools to Optimize CRISPR/Cas9 Experiments to Reduce Off-Target Effects.
    Naeem M; Alkhnbashi OS
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Genome Editing and Transcriptional Control Capabilities Reveals Hierarchies among Diverse CRISPR/Cas Systems in Human Cells.
    Escobar M; Li J; Patel A; Liu S; Xu Q; Hilton IB
    ACS Synth Biol; 2022 Oct; 11(10):3239-3250. PubMed ID: 36162812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.
    Anzalone AV; Koblan LW; Liu DR
    Nat Biotechnol; 2020 Jul; 38(7):824-844. PubMed ID: 32572269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.
    Dey A; Nandy S
    Recent Pat Anticancer Drug Discov; 2021; 16(4):460-468. PubMed ID: 34911411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.